/XINT.ST
XINT.ST Stock - Xintela AB (publ)
Healthcare|BiotechnologySTO
$0.27-0.74%
$0.00 (-0.74%) • Dec 23
40
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.25
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.30
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XINT.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.27 – $0.27
TARGET (TP)$0.31
STOP LOSS$0.25
RISK/REWARD1:2.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.36
52W High$0.70
52W Low$0.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.21M | $78,000 | N/A | N/A | N/A |
| Gross Profit | $4.21M | $78,000 | $-3,786,000 | $-3,495,000 | $-3,569,000 |
| Gross Margin | 100.0% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-39,447,000 | $-57,238,000 | $-69,062,000 | $-43,556,000 | $-33,897,000 |
| Net Income | $-39,190,000 | $-54,083,000 | $-66,217,000 | $-58,932,000 | $-52,924,000 |
| Net Margin | -929.8% | -69337.2% | N/A | N/A | N/A |
| EPS | $-0.07 | $-0.13 | $-0.37 | $-0.42 | $-0.64 |
Company Overview
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
XINT.STBeat Rate
80%
Last 5 quarters
Avg Surprise
+39.1%
EPS vs Estimate
Beats / Misses
4/0
1 met exactly
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
+30.3%
$-0.03vs$-0.04
Q2 24
+51.5%
$-0.02vs$-0.04
Q2 24
+81.8%
$-0.02vs$-0.11
Q3 24
No data
Q4 24
No data
Q2 25
0.0%
$-0.01vs$-0.01
Q4 25
+31.8%
$-0.01vs$-0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 4, 2025 | $-0.02 | $-0.01 | +31.8% | ✓ BEAT |
Q2 2025 | May 23, 2025 | $-0.01 | $-0.01 | 0.0% | = MET |
Q4 2024 | Dec 31, 2024 | — | $-0.02 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.01 | — | — |
Q2 2024 | Jun 29, 2024 | $-0.11 | $-0.02 | +81.8% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.04 | $-0.02 | +51.5% | ✓ BEAT |
Q4 2023 | Dec 30, 2023 | $-0.04 | $-0.03 | +30.3% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.06 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.05 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.09 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.10 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.14 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.11 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.18 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.07 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.08 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.06 | — | — |
Q1 2021 | Feb 26, 2021 | — | $-0.08 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.44 | — | — |
Latest News
Loading news...
Frequently Asked Questions about XINT.ST
What is XINT.ST's current stock price?
Xintela AB (publ) (XINT.ST) is currently trading at $0.27 per share. The stock has moved -0.74% today.
What is the analyst price target for XINT.ST?
No analyst price targets are currently available for this stock.
What sector is Xintela AB (publ) in?
Xintela AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is XINT.ST's market cap?
Xintela AB (publ) has a market capitalization of $0.19 billion, making it a small-cap company.
Does XINT.ST pay dividends?
No, Xintela AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACARIX.ST
Acarix AB (publ)
$0.28
Mkt Cap: $0.3B
ACE.ST
Ascelia Pharma AB (publ)
$3.17
Mkt Cap: $0.4B
BIOWKS.ST
Bio-Works Technologies AB (publ)
$2.25
Mkt Cap: $0.2B
ELIC.ST
Elicera Therapeutics AB (publ)
$5.59
Mkt Cap: $0.3B
IMMU.ST
Mendus AB (publ)
$5.30
Mkt Cap: $0.3B
IRLAB-A.ST
IRLAB Therapeutics AB (publ)
$1.97
Mkt Cap: $0.2B
IVACC.ST
Intervacc AB (publ)
$0.92
Mkt Cap: $0.3B
KDEV.ST
Karolinska Development AB (publ)
$0.43
Mkt Cap: $0.1B
LIPUM.ST
Lipum AB (publ)
$14.55
Mkt Cap: $0.3B
NANEXA.ST
Nanexa AB (publ)
$4.21
Mkt Cap: $0.7B
Explore stocks similar to XINT.ST for comparison